Please use this identifier to cite or link to this item:
Title: Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Austin Authors: Testro, Adam G ;Wongseelashote, Sarah;Angus, Peter W ;Gow, Paul J 
Affiliation: Victorian Liver Transplant Unit
Gastroenterology and Hepatology
Issue Date: 3-Sep-2008
Publication information: Journal of Gastroenterology and Hepatology 2008; 23(10): 1535-40
Abstract: Studies suggest that terlipressin is effective in the treatment of hepatorenal syndrome (HRS). However, factors predicting response to therapy and the long-term outcome of patients have not been defined.We reviewed all patients from our institution treated with terlipressin between July 1, 2001 and December 31, 2005 for HRS. Follow up continued until June 30, 2006. HRS was defined according to the International Ascites Club. The following data were retrieved: age, gender, etiology of liver disease, Child-Pugh score, HRS precipitant, therapy duration, creatinine at day 0 and end of treatment, adverse events, and patient outcome.Sixty-nine patients were included. Forty-nine episodes (71%) of HRS were type 1, and 20 episodes (29%) type 2. Forty-one (59.4%) patients responded to terlipressin. Two variables predicted renal function improvement: type 1 HRS and age. Twenty-one (30.4%) patients survived; 17 (81%) had type 1 HRS while four (19%) had type 2 HRS (P = 0.27). The only factor predicting transplant-free survival was type 1 HRS. No patients with type 2 HRS survived without transplantation (P = 0.02).The only factor predicting transplant-free survival following terlipressin therapy is the presence of type 1 HRS. Therefore, it is difficult to justify the use of this drug in patients with type 2 HRS who are not liver transplant candidates.
DOI: 10.1111/j.1440-1746.2007.05176.x
Journal: Journal of Gastroenterology and Hepatology
Type: Journal Article
Subjects: Adult
Cardiovascular Agents.therapeutic use
Hepatorenal Syndrome.drug
Kaplan-Meier Estimate
Kidney.drug effects.physiopathology
Liver Transplantation
Lypressin.analogs & derivatives.therapeutic use
Middle Aged
Patient Selection
Retrospective Studies
Risk Assessment
Severity of Illness Index
Time Factors
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.